Literature DB >> 11948876

A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts.

M Nguyen1, C Claparols, J Bernadou, B Meunier.   

Abstract

It is currently believed that isoniazid (INH) is oxidised inside Mycobacterium tuberculosis to generate, by covalent attachment to the nicotinamide ring of NAD(H) (beta-nicotinamide adenine dinucleotide), a strong inhibitor of InhA, an enzyme essential for mycolic acid biosynthesis. This work was carried out to characterise the InhA inhibitors (named INH-NAD(H) adducts) which are generated, in the presence of the nicotinamide coenzyme NAD+, by oxidation of INH with manganese(III) pyrophosphate, a nonenzymatic and efficient oxidant used to mimic INH activation by the catalase-peroxidase KatG inside M. tuberculosis. The oxidation process is almost complete in less than 15 minutes (in comparison to the slow activation obtained in the KatG-dependent process (2.5 hours) or in the nonenzymatic O2/Mn(II)-dependent activation (5 hours)). The alkylation of NAD+ by the postulated isonicotinoyl radical generates, in solution, a family of INH-NAD(H) adducts. Analyses with liquid chromatography/electrospray ionisation mass spectrometry (LC/ESI-MS) and experiments performed with 18O- and 2H-labelled substrates allowed us to propose two open and four hemiamidal cyclised dihydropyridine structures as the main forms present in solution; these result from the combination of the isonicotinoyl radical and the nicotinamide part of NAD+. A small amount of a secondary oxidation product was also detected. Structural data on the forms present in solution should help in the design of inhibitors of enzymes involved in the biosynthesis of mycolic acids to act as potential antituberculosis drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11948876     DOI: 10.1002/1439-7633(20011203)2:12<877::AID-CBIC877>3.0.CO;2-V

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  12 in total

1.  Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design.

Authors:  Eduardo Henrique Silva Sousa; Luiz Augusto Basso; Diógenes S Santos; Izaura Cirino Nogueira Diógenes; Elisane Longhinotti; Luiz Gonzaga de França Lopes; Icaro de Sousa Moreira
Journal:  J Biol Inorg Chem       Date:  2011-09-28       Impact factor: 3.358

2.  Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis.

Authors:  Argyrides Argyrou; Lianji Jin; Linda Siconilfi-Baez; Ruth H Angeletti; John S Blanchard
Journal:  Biochemistry       Date:  2006-11-28       Impact factor: 3.162

3.  New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP.

Authors:  Argyrides Argyrou; Matthew W Vetting; John S Blanchard
Journal:  J Am Chem Soc       Date:  2007-07-18       Impact factor: 15.419

4.  A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.

Authors:  Sebabrata Mahapatra; Lisa K Woolhiser; Anne J Lenaerts; John L Johnson; Kathleen D Eisenach; Moses L Joloba; W Henry Boom; John T Belisle
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

5.  Elucidating the structural basis of diphenyl ether derivatives as highly potent enoyl-ACP reductase inhibitors through molecular dynamics simulations and 3D-QSAR study.

Authors:  Pharit Kamsri; Auradee Punkvang; Patchareenart Saparpakorn; Supa Hannongbua; Stephan Irle; Pornpan Pungpo
Journal:  J Mol Model       Date:  2014-06-17       Impact factor: 1.810

6.  Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities.

Authors:  Christine E Cade; Adrienne C Dlouhy; Katalin F Medzihradszky; Saida Patricia Salas-Castillo; Reza A Ghiladi
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

Review 7.  Diversity in enoyl-acyl carrier protein reductases.

Authors:  R P Massengo-Tiassé; J E Cronan
Journal:  Cell Mol Life Sci       Date:  2009-05       Impact factor: 9.261

8.  In vitro inhibition of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid.

Authors:  Stéphanie Ducasse-Cabanot; Martin Cohen-Gonsaud; Hedia Marrakchi; Michel Nguyen; Didier Zerbib; Jean Bernadou; Mamadou Daffé; Gilles Labesse; Annaïk Quémard
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

9.  Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis.

Authors:  Michel Nguyen; Annaïk Quémard; Sylvain Broussy; Jean Bernadou; Bernard Meunier
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

10.  Comparative analysis of mycobacterial NADH pyrophosphatase isoforms reveals a novel mechanism for isoniazid and ethionamide inactivation.

Authors:  Xu-De Wang; Jing Gu; Ting Wang; Li-Jun Bi; Zhi-Ping Zhang; Zong-Qiang Cui; Hong-Ping Wei; Jiao-Yu Deng; Xian-En Zhang
Journal:  Mol Microbiol       Date:  2011-11-03       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.